Articles published in Journal of Pharmacogenomics & Pharmacoproteomics have been cited by esteemed scholars and scientists all around the world. Journal of Pharmacogenomics & Pharmacoproteomics has got h-index 12, which means every article in Journal of Pharmacogenomics & Pharmacoproteomics has got 12 average citations.

Following are the list of articles that have cited the articles published in Journal of Pharmacogenomics & Pharmacoproteomics.

  2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Total published articles

30 56 30 30 13 4 7 15 13 20 25 12 35 13 2

Research, Review articles and Editorials

0 6 2 4 1 1 6 14 12 17 25 12 34 7 2

Research communications, Review communications, Editorial communications, Case reports and Commentary

30 50 28 8 2 0 1 1 1 2 0 0 0 0 0

Conference proceedings

0 0 0 0 0 0 35 102 83 47 82 0 0 0 0

Citations received as per Google Scholar, other indexing platforms and portals

35 55 58 71 61 49 63 48 72 63 23 8 6 0 0
Journal total citations count 613
Journal impact factor 2.31
Journal 5 years impact factor 3.74
Journal cite score 4.86
Journal h-index 12
Important citations

Hyperoxia and modulation of pulmonary vascular and immune responses in COVID-19

Glycogen synthase kinase-3: A putative target to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic

Role of dietary antioxidants in human metapneumovirus infection

nfectious mononucleosis and hepatic function

Oxidative stress and its association with covid-19: A narrative review

Anti?inflammatory and antiviral roles of hydrogen sulfide: Rationale for considering H2S donors in COVID?19 therapy

Vascular manifestations of COVID-19–thromboembolism and microvascular dysfunction

Flavonoids activation of the transcription factor Nrf2 as a hypothesis approach for the prevention and modulation of SARS-CoV-2 infection severity

Evaluation of the expression level of 12/15 lipoxygenase and the related inflammatory factors (CCL5, CCL3) in respiratory syncytial virus infection in mice model

Up-regulation of nuclear factor E2-related factor 2 (Nrf2) represses the replication of SVCV

Nrf2 Activator PB125® as a Potential Therapeutic Agent against COVID-19

Can Activation of NRF2 Be a Strategy against COVID-19?

 Therapeutic modulation of virus-induced oxidative stress via the Nrf2-dependent antioxidative pathway

Redox Biology of Respiratory Viral Infections

Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection

Morales-Vásquez, Lilliana, et al. "Demographics, clinical characteristics, IFNL3-and IFNL4-polymorphisms in a cohort of hepatitis C patients from Puerto Rico." Puerto Rico health sciences journal 33.4 (2014): 177.

Duconge, J. "Population heterogeneity and genomic admixture: relevance for global pharmacogenetics." J. Pharmacogenom. Pharmacoproteomics 5 (2014): 5.

Valentín, Isa I., et al. "Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans." Puerto Rico health sciences journal 33.3 (2014): 97.

Nishant, T., et al. "Pharmacogenomics-Personalized treatment of cancer, diabetes and cardiovascular diseases." J Pharmacogenomics Pharmacoproteomics 2 (2011): 107.

Duconge, Jorge, et al. "A novel admixture-based pharmacogenetic approach to refine warfarin dosing in Caribbean Hispanics." PloS one 11.1 (2016): e0145480.